eyal

­

About eyal

This author has not yet filled in any details.
So far eyal has created 84 blog entries.

Quark will present at 2015 American Transplant Congress, May 5, 2015

April 5th, 2015|

Relationship Between Delayed Graft Function (DGF) Severity and Predicted DGF Risk

E. Squiers,1 B. Irish,1 D. Odenheimer,1 S. Erlich,1 J. Grinyo, S. Feng, On Behalf of Quark DGF Study Investigators.

1Quark, Fremont
2UCSF, SF
3U of Barcelona, BCN, Spain.

Meeting: 2015 American Transplant Congress

Abstract number: 448

Keywords: Cadaveric organs, Graft function, Kidney transplantation, Outcome

 

http://www.atcmeetingabstracts.com/abstract/relationship-between-delayed-graft-function-dgf-severity-and-predicted-dgf-risk/

Quark will present at TIDES 2015, at the Town and Country Hotel in San Diego, CA, May 3-6, 2015

April 3rd, 2015|

Results of a Large Phase 2 siRNA Study: Target Expression Translates to Therapeutic Outcomes
Results of large (N=326) P2 study showed QPI-1002, a systemically administered siRNA targeting p53, significantly reduced the clinical endpoint of severity of delayed graft function post-transplant, especially in kidneys from older donors (p<0.016); which are known to have increased p53. A P3 […]

Quark will present at The 7th GTC Ocular Disease Drug Discovery Conference. San Diego, CA. March 18-19, 2015.

February 18th, 2015|

A Synthetic Chemically Modified siRNA Targeting Caspase 2 as a Therapeutic Agent for Ocular Neuroprotection

https://www.gtcbio.com/conferences/ocular-diseases-drug-discovery-speakers

Quark announces patent approval for Methods for delivery of siRNA to the spinal cord and therapies arising therefrom

December 2nd, 2014|

The present application relates at least in part to methods for the administration of small interfering RNAs (siRNAs) to the spinal cord of a human or animal patient and also to a method of treatment for spinal cord injury and other diseases and disorders of the CNS. In particular, the application discloses methods to deliver […]

Quark announces Patent Approval for Oligonucleotide compounds comprising non-nucleotide overhangs

October 14th, 2014|

The invention relates to siRNA compounds comprising one non-nucleotide moiety covalently attached to at least one of the sense or antisense strands to down-regulate the expression of human genes. The invention also relates to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier and to methods of treating and/or preventing the incidence or severity […]

Quark will present at Targeting Ocular Disorders. Boston, MA. October 6-7, 2014

September 6th, 2014|

A Synthetic Chemically Modified siRNA Targeting Caspase-2 as a Therapeutic Agent for Ocular europrotection
Elena Feinstein, M.D., Ph.D., CSO, Quark Pharmaceuticals
Caspase-2 is a pro-apoptotic gene specifically expressed and activated in retinal
ganglion cells following acute optic nerve injury or intraocular pressure increase.
Intravitreal administration of QPI1007 (a syntehticsiRNA targeting caspase-2)
demonstrated local RNA interference, lack of inflammatory effects and […]

Quark announces patent approval for Sirna compounds comprising terminal substitutions

August 5th, 2014|

The invention relates to modified siRNA compounds which down-regulate target gene expression, to pharmaceutical compositions comprising such compounds and to methods of treating and/or preventing the incidence or severity of various diseases or conditions associated with the genes and/or symptoms associated with such diseases or conditions.

Read More…

Quark Pharmaceuticals Reports Favorable Results from Phase II Clinical Trial Evaluating Investigational siRNA QPI-1002

July 28th, 2014|

San Francisco, CA – July 28, 2014 – Today, Quark Pharmaceuticals, Inc. reported data from a randomized, double-blinded, placebo-controlled multicenter Phase II clinical trial (QRK.006B; ClinicalTrials.gov identifier: NCT00802347) of QPI-1002, a synthetic chemically modified siRNA acting to reduce p53 RNA and protein levels, for the prophylaxis of delayed graft function (DGF) in deceased donor kidney […]

Quark will present at 2014 World Transplant Congress July 26-31st 2014

July 26th, 2014|

Treatment with QPI-1002, a Short Interfering (SI) RNA for the

Prophylaxis of Delayed Graft Function. V. Peddi,1 L. Ratner,2 M.

Cooper,2 O. Gaber,2 S. Feng,2 P. Tso,2 V. Bowers,2 R. Naraghi,2 K. Budde,2

Polinsky,3 E. Squiers,3 S. Erlich,3 Study Investigators Group.2 1CPMC,

San Francisco, CA; 2Multiple Institutions; 3Quark Pharmaceuticals,

Fremont.

Introduction: Delayed graft function (DGF) can adversely affect deceased donor

renal transplant […]

Quark Announces Completion of Phase II Trial Evaluating QPI-1002 for Prevention of Delayed Graft Function in Kidney Transplant Patients

July 1st, 2014|

Results to be presented at the World Transplant Conference on July 28, 2014

Fremont, CA, July 1, 2014 – Quark Pharmaceuticals, Inc. today reported completion of a randomized, placebo-controlled multicenter Phase II trial of QPI-1002 for the prophylaxis of delayed graft function (DGF) in ESRD dialysis-dependent patients undergoing deceased donor kidney transplantation. The results of the […]